Medications + Contraindications

Fast Medication Triage

Start with the stop conditions. If none of them apply, keep reading with the assumption that interaction tables are still weaker than your full medication picture.

Why Medication Mistakes Get Expensive Fast

If you get storage wrong, you may lose potency. If you get sourcing wrong, you may waste money or trust the wrong batch. If you get an interaction wrong, you can create a medical emergency or destabilize an illness you were already managing.

This page is educational and harm-reduction oriented. It is not medical advice, and it is not clearance. The safest move is still a conversation with a prescriber who understands your full medication picture. Where that conversation is not available, the minimum standard is understanding the mechanism well enough to know when the answer is simply no.

Absolute Contraindications

These are not “proceed carefully” situations. These are the combinations where the risk signal is strong enough that the adult move is to stop the plan.

Lithium + Classical Psychedelics

Lithium remains the clearest hard stop in the public psychedelic interaction literature. Published report analysis found a pronounced seizure signal with classic psychedelic plus lithium combinations, while lamotrigine did not show the same pattern. This is why the lithium warning is categorical instead of probabilistic.

If you are on lithium, do not microdose. Do not test a “very small amount.” Do not treat this like a tolerance or timing puzzle. The right conversation is about your treatment plan with your prescriber, not about slipping psychedelics on top.

Tramadol + Psychedelics

Tramadol carries both serotonergic and seizure-threshold concerns on its own. Layering psilocybin or LSD on top of it is a bad pharmacological stack, not a subtle judgment call. Treat tramadol as a stop condition, not as a drug you can “work around” with lower psychedelic doses.

Pregnancy, Breastfeeding, and Trying To Conceive

Operationally, this belongs in the no-go bucket. There are no controlled human safety data for psilocybin or LSD in pregnancy or breastfeeding, and modern psychedelic trials exclude these populations entirely. That evidence gap is not a green light.

The strongest direct signal we have is preclinical, not human: a 2025 Nature Communications postpartum mouse study found adverse long-term effects in treated dams and behavioral effects in adult offspring after lactational exposure. Mouse data does not prove human harm. It does reinforce the correct posture here: precaution, not home experimentation.

High-Caution Interactions

High caution means the answer depends on the specific medication, dose, history, and reason you are taking it. It does not mean the combination is casually acceptable.

SSRIs + Psychedelics

SSRIs are the most common interaction question because they are the most common psychiatric medication class in the target population. The most common outcome is weaker-than-expected psychedelic effects, not a dramatic emergency. Chronic SSRI exposure downregulates the receptor system psychedelics rely on, which means many people report muted threshold signals or needing more than expected to feel anything.

That does not make the combination harmless. The risk floor is still serotonergic stacking, especially at higher doses, in polypharmacy, or with additional serotonergic agents. Fluvoxamine deserves extra caution because it can alter metabolism while still muting the subjective read. Feeling less while processing more is not a good calibration state.

Do not turn this into a self-designed taper project. Washout timing and taper timing are different problems. Half-life tables tell you when a drug leaves the bloodstream; they do not tell you how to withdraw from it safely.

SNRIs + Psychedelics

SNRIs carry the same broad serotonergic concerns as SSRIs, with added norepinephrine activation layered on top. In practice, that means the same blunting problem plus a greater chance of feeling activated, overstimulated, or physically strained if you overshoot.

Venlafaxine is worth singling out because discontinuation can hit hard and fast. If the only way a microdosing plan works is by abruptly destabilizing an SNRI regimen, the plan is defective.

MAOIs + Psychedelics

MAOIs are not one flat category. Hard red lines: MDMA + any MAOI and 5-MeO-DMT + any MAOI. Those pairings have documented severe toxicity and death reports. Psilocybin, LSD, and DMT with pharmaceutical MAOIs still do not belong in casual self-experimentation, but the evidence does not support pretending every pairing has the same proof-strength. Treat those as clinician-level, no-DIY chemistry cases.

This matters especially in ayahuasca contexts because ayahuasca already contains MAOI activity. Do not stack a pharmaceutical MAOI on top.

Bipolar Disorder, Psychotic-Spectrum History, and Family History

Bipolar I disorder, schizophrenia, schizoaffective disorder, and strong personal or family history in that direction all move this out of casual experimentation. Most modern psychedelic trials exclude these populations for a reason. Case reports of mania and psychotic destabilization exist, and newer population data reinforce caution, even though the highest-risk cohort signal comes from people whose hallucinogen use was serious enough to lead to emergency or hospital care rather than from the entire population of users.

The nuance matters: bipolar II research is emerging, and a small supervised trial in treatment-resistant bipolar II depression did not show treatment-emergent mania. That is not a license for unsupervised home microdosing. It is a sign that the supervised clinical question is more complicated than a simple blanket statement.

Antipsychotics + Psychedelics

Antipsychotics often blunt or block psychedelic effects because they oppose the receptor system psychedelics depend on. The more important issue, though, is why you are on the antipsychotic in the first place. These medications are commonly prescribed in exactly the populations where psychedelic destabilization risk is highest.

Do not stop an antipsychotic to “unlock” a psychedelic effect. That trade is usually more dangerous than the blocked effect you were frustrated by.

Moderate Interactions That Still Need Specific Knowledge

Moderate does not mean trivial. It means the mechanism is clearer, the catastrophic risk is lower, and the practical problem is often distortion, blunting, or overstimulation rather than a direct emergency pathway.

Benzodiazepines

Benzodiazepines do not create the same serotonergic risk picture. They usually blunt or terminate psychedelic effects. That is why they appear in crisis-response protocols. The real danger is destabilizing a benzodiazepine dependence pattern in order to clear the way for psychedelic experimentation. Do not do that.

Stimulants

Amphetamine, methylphenidate, and lisdexamfetamine are common in the microdosing-curious population. The practical risk is a narrowed subjective window: more heart rate, more jaw tension, more agitation, less clean threshold signal. Timing matters. Stacking a stimulant and a psychedelic at once is more likely to create noise than clarity.

Cannabis

Cannabis is less a pharmacological contraindication than a calibration destroyer. It can potentiate psychedelic effects, amplify anxiety, and make it much harder to attribute what the dose actually did. During discovery or recalibration, separating cannabis from psychedelic dose days is cleaner and safer.

Bupropion

Bupropion is usually less troublesome than serotonergic antidepressants because its main action is on norepinephrine and dopamine, not serotonin. That said, it lowers seizure threshold. For most people that means caution, not prohibition. If you already have seizure risk factors, this becomes more than a footnote.

Mirtazapine, TCAs, and Lamotrigine

Mirtazapine and many tricyclics can blunt psychedelic effects and complicate the read without looking like classic SSRI cases. Lamotrigine is the important contrast case: it does not carry the same seizure warning signal as lithium, but it still sits inside a broader bipolar-management context that should make you more conservative, not less.

Decision Framework

1. Ask whether your medication is a hard stop. Lithium, tramadol, MDMA + MAOI, 5-MeO-DMT + MAOI, and ayahuasca plus a pharmaceutical MAOI should end the idea. Other pharmaceutical MAOI cases belong in clinician-level, no-DIY review.
2. Ask whether the stack is serotonergic. SSRIs, SNRIs, trazodone, buspirone, TCAs, and multi-drug combinations deserve a narrower margin for error.
3. Ask whether you are planning to destabilize an existing prescription to make psychedelics work. If yes, the plan is already off the rails.
4. Ask whether you are on multiple neuroactive medications. Polypharmacy is where internet tables fail fastest.
5. Ask whether pregnancy, breastfeeding, bipolar-spectrum history, psychotic-spectrum history, or antipsychotic treatment changes the risk class entirely.
6. Ask whether a prescriber can be involved, even indirectly. “I’m evaluating serotonin-pathway supplements and want to understand interaction risk” is often enough to open the conversation.

Emergency Recognition: Serotonin Syndrome

Serotonin syndrome exists on a spectrum. Mild signs include agitation, sweating, dilated pupils, rapid pulse, tremor, and diarrhea. Moderate signs include marked hyperreflexia, clonus, worsening agitation, and rising temperature. Severe signs include high fever, rigidity, seizures, delirium, loss of consciousness, or dangerous arrhythmia.

If the pattern looks moderate or worse, call emergency services. Tell responders what was taken and what medications are involved. Your life matters more than the awkwardness of the disclosure.